Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study
Objective: To evaluate three-year outcomes from the ND0612 BeyoND study. Background: Investigational ND0612 is in development as a 24-hour continuous, subcutaneous infusion of liquid levodopa/carbidopa…Basal ganglia shape in de novo Parkinson’s disease patients can predict the onset of Levodopa Induced Dyskinesias
Objective: In the current study, we aimed to examine structural MRI data from a large sample of de novo PD patients and to identify potential…Characterisation of the pharmacokinetic profile of L-DOPA in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of L-3,4-dihydroxyphenylalanine (L-DOPA) in the common marmoset (Callithrix jacchus). Background: The common marmoset has been used to model…Levodopa-entacapone-carbidopa intestinal gel infusion for Parkinson’s disease: An analysis of data collected from the Swedish national register of Parkinson’s disease.
Objective: To investigate efficacy, tolerability, and safety of levodopa-entacapone-carbidopa intestinal gel (LECIG) in Parkinson’s disease. Background: LECIG was introduced in 2019. The approval was based…Clinical analysis of Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease. A single-center retrospective cohort study.
Objective: To evaluate clinical impact of treatment (LCIG) infusion in patients with advanced PD. Background: Levodopa/carbidopa intestinal gel (LCIG) infusion has demonstrated more stable plasma…Risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia patients with Parkinson’s disease: a meta-analysis of randomized controlled trials
Objective: The present meta-analysis aims to find out association between risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia (LID) patients with Parkinson’s disease (PD).…The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
Objective: To assess the effect of the metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM) AZD8529 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis-like behaviours (PLBs)…Response to Levodopa in Parkinson´s Disease Over Time. A 4-year Follow-up Study.
Objective: The aim of the present study was to analyze the response to levodopa in Parkinson´s disease (PD) patients with motor fluctuations followed up for…Effects of NE3107 anti-inflammatory treatment on motor activity and neurodegenerative features of Parkinson’s disease in a marmoset monkey model
Objective: To demonstrate the effects of an oral, anti-inflammatory agent, NE3107, on motor activity, levodopa-induced dyskinesia (LID) induction, and neuron survival in a marmoset model…Analysis of levodopa use in patients with Parkinson’s Disease during pregnancy: a systematic review of the last twenty years
Objective: To evaluate the role of oral levodopa in patients with Parkinson’s disease (PD) during pregnancy, using the available literature, in order to determine the…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 57
- Next Page »